ARS Pharmaceuticals, Inc (SPRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has a cash flow conversion efficiency ratio of -0.381x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.48 Million) by net assets ($114.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ARS Pharmaceuticals, Inc to measure how much of total assets are equity-financed.
ARS Pharmaceuticals, Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SPRY cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
ARS Pharmaceuticals, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SA Corporate Real Estate Fund Managers Ltd
JSE:SAC
|
0.023x |
|
Sikarin Public Company Limited
BK:SKR
|
0.035x |
|
Guggenheim Active Allocation Fund
NYSE:GUG
|
N/A |
|
Universal Cables Limited
NSE:UNIVCABLES
|
-0.002x |
|
Shanghai Shentong Metro Co Ltd
SHG:600834
|
-0.012x |
|
Maxic Technology Inc. A
SHG:688458
|
N/A |
|
ADENTRA INC.
F:UQ0
|
-0.009x |
|
W olf Photoelectric Technology Ltd
SHE:002962
|
0.015x |
Annual Cash Flow Conversion Efficiency for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see SPRY market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.26 Million | $-170.87 Million | -1.495x | -2934.56% |
| 2024-12-31 | $256.80 Million | $13.55 Million | 0.053x | +120.54% |
| 2023-12-31 | $230.76 Million | $-59.27 Million | -0.257x | -74.87% |
| 2022-12-31 | $272.89 Million | $-40.08 Million | -0.147x | -126.15% |
| 2021-12-31 | $-31.27 Million | $-17.56 Million | 0.562x | +187.00% |
| 2020-12-31 | $-14.05 Million | $9.07 Million | -0.646x | -119.14% |
| 2019-12-31 | $-5.60 Million | $-18.90 Million | 3.373x | +463.71% |
| 2018-12-31 | $18.20 Million | $-16.88 Million | -0.927x | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more